MeritValue

Sigyn Therapeutics, Inc.

SIGYdata completeness 75%10 fiscal years on file
The thesis, from the filings

Sigyn Therapeutics, Inc. earns about -1270% on equity, and has bought back 82% of its shares over 5 years. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own
FigureFY 2020FY 2021FY 2022FY 2023FY 2024
Revenue—————
Net income−$1.26M1−$3M2−$2.93M3−$4.15M4−$3.34M4
Operating cash flow−$829,8095−$1.77M6−$1.83M7−$1.38M8−$872,4368
Capital expenditure—$29,2649$86010——
Free cash flow (derived)—−$1.8M6−$1.83M7——
Total debt——$2.28M11$2.51M12$2.2M13
Cash & equivalents$84,40214$340,95615$8,35616$11,69017$12,14417
Diluted shares7.4M36.4M934,9151.1M1.3M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$33.45
your share of equity
Profit it earned you last year
−$25.07
Free cash flow it threw off
—
Debt you’d be carrying
$16.48

10 shares is a claim on −$33.45 of net worth that earned you −$25.07 last year, against $16.48 of debt.

iii. Is this a good business?
Moat signal · return on equity
-1270% avg · 5y
FY20 -1270%FY21 —FY22 —FY23 —FY24 —

It earned an average -1270% on equity over 5 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →
Management signal · capital allocation
−82% shares · 5y

Share count is down 82% over 5 years — management has been buying back stock, quietly handing owners a bigger slice. Total debt has held roughly steady.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
only 2 years of FCF (need ≥3) — model not applicable
DCF · Growth Exit 5Y
not applicable
only 2 years of FCF (need ≥3) — model not applicable
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2020-12-31 · accession 0001493152-22-007382 (NetIncomeLoss)
  2. 10-K · period ending 2021-12-31 · accession 0001493152-23-009883 (NetIncomeLoss)
  3. 10-K · period ending 2022-12-31 · accession 0001493152-24-007240 (NetIncomeLoss)
  4. 10-K · period ending 2023-12-31 · accession 0001641172-25-004740 (NetIncomeLoss)
  5. 10-K · period ending 2020-12-31 · accession 0001493152-22-007382 (NetCashProvidedByUsedInOperatingActivities)
  6. 10-K · period ending 2021-12-31 · accession 0001493152-23-009883 (NetCashProvidedByUsedInOperatingActivities)
  7. 10-K · period ending 2022-12-31 · accession 0001493152-24-007240 (NetCashProvidedByUsedInOperatingActivities)
  8. 10-K · period ending 2023-12-31 · accession 0001641172-25-004740 (NetCashProvidedByUsedInOperatingActivities)
  9. 10-K · period ending 2021-12-31 · accession 0001493152-23-009883 (PaymentsToAcquirePropertyPlantAndEquipment)
  10. 10-K · period ending 2022-12-31 · accession 0001493152-24-007240 (PaymentsToAcquirePropertyPlantAndEquipment)
  11. 10-K · period ending 2022-12-31 · accession 0001493152-23-009883 (LongTermDebt)
  12. 10-K · period ending 2023-12-31 · accession 0001493152-24-007240 (LongTermDebt)
  13. 10-K · period ending 2024-12-31 · accession 0001641172-25-004740 (LongTermDebt)
  14. 10-K · period ending 2020-12-31 · accession 0001493152-22-007382 (CashAndCashEquivalentsAtCarryingValue)
  15. 10-K · period ending 2021-12-31 · accession 0001493152-23-009883 (CashAndCashEquivalentsAtCarryingValue)
  16. 10-K · period ending 2022-12-31 · accession 0001493152-24-007240 (CashAndCashEquivalentsAtCarryingValue)
  17. 10-K · period ending 2023-12-31 · accession 0001641172-25-004740 (CashAndCashEquivalentsAtCarryingValue)